knowledge -WSS

knowledge

author：explore 2025-09-28 15:20:48 - browse：68771

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： California wildfire smoke linked to 52,000 early deaths, study says

hotspot

WSS

STAT Virtual Event: ASCO Recap, Live!

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

ALS patient reclaims some autonomy thanks to wearable 'robot'

Donor acceptance rates hint at racial, gender bias in heart transplants: study

The Readout: Lenmeldy, GLP

Lilly's Alzheimer's drug donanemab backed by FDA advisers

knowledge

knowledge

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

Eliminate the waiting period for sterilization covered by Medicaid

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Statins may not be needed by millions of people, study suggests

At least 13 dead in Texas as scorching temps continue

Scientists boost immune system in aging mice by making it youthful

New air purifier tech could be key to improving indoor air quality

Medical device trials still don't enroll enough women, study finds

Moonlake's readout produced a cash windfall. Risks remain

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

focus

STAT Virtual Event: ASCO Recap, Live!

Moderna says combo Covid

New report analyzes digital physical therapy solutions' effectiveness

Eliminate the waiting period for sterilization covered by Medicaid

Eliminate the waiting period for sterilization covered by Medicaid

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

explore

focus

hotspot

focus